OmniaSecure MRI SureScan Lead Model 3930M
Medtronic, Inc. · Decision date Apr 22, 2025
What did the FDA approve?
FDA approved PMA P240036 for the OmniaSecure MRI SureScan Lead Model 3930M on April 22, 2025. The applicant is Medtronic, Inc., and the product code is NVY under the permanent defibrillator electrodes category.
The approval statement describes the lead as single use in the right ventricle for pacing, sensing, cardioversion, and defibrillation when a cardiac implantable electronic device is indicated for patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. It also includes adolescent pediatric patients who are at least 30 kg and at least 12 years of age, and whose cardiac anatomy is conducive to RV coil placement.
The database record does not include a supplement type or supplement reason, so no additional relationship to a prior PMA is established by the supplied fields. The statement reports an intended purpose, not independent proof of safety or clinical effectiveness.
FDA approval order statement
The Model 3930M lead is intended for single use in the right ventricle for pacing, sensing, cardioversion, and defibrillation when a cardiac implantable electronic device is indicated to treat patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias.This includes adolescent pediatric patients who are at least 30 kg and are also at least 12 years of age, and whose cardiac anatomy is conducive to RV coil placement.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 22, 2025
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240036
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- NVY
- Decision code
- APPR
- Decision date
- Apr 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Permanent defibrillator electrodes.
- Applicant
- Medtronic, Inc.
- Product code
- NVY
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240036 received
Application receipt date recorded by FDA.
P240036 · FDA decision
APPR
P240036/S007 · Related supplement
OmniaSecure MRI SureScan Lead Model 3930M
Timeline entries are records held by MedtechLedger for P240036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
OmniaSecure MRI SureScan Lead Model 3930MP240036/S007 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P240036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records